CERo Therapeutics (CERO) posts investor presentation and CER-1236 Phase 1 AML update

Rhea-AI Filing Summary

CERo Therapeutics Holdings, Inc. filed a current report describing new investor and clinical communications. The company furnished an updated corporate presentation as an exhibit, which it plans to use in meetings with investors, analysts and others. This presentation is furnished rather than filed, meaning it is not automatically subject to certain Exchange Act liability provisions.

The company also issued a press release titled “CERo Therapeutics Provides Clinical Update on Phase 1 Trial of CER-1236 in AML (CertainT-1) Highlighting Key Safety Data and Platelet Transfusion-Free Interval Observed in a Patient with Myelodysplastic Syndrome/AML.” The press release and the presentation are included as exhibits, giving readers access to the latest clinical update and investor materials.

8-K Event Classification

3 items: 7.01, 8.01, 9.01

3 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false 0001870404 0001870404 2026-01-07 2026-01-07 0001870404 CERO:CommonStockParValue0.0001PerShareMember 2026-01-07 2026-01-07 0001870404 CERO:WarrantsEachWarrantExercisableForOneTwothousandthsOfShareOfCommonStockMember 2026-01-07 2026-01-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or Section 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 7, 2026

CERO THERAPEUTICS HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-40877		81-4182129
(State or other jurisdiction of incorporation or organization)		(Commission File Number)		(I.R.S. Employer Identification Number)

201 Haskins Way, Suite 230, South San Francisco, CA		94080
(Address of principal executive offices)		(Zip Code)

(650) 407-2376

Registrant’s telephone number, including area code

Not applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		CERO		None
Warrants, each warrant exercisable for one two-thousandths of a share of Common Stock		CEROW		None

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On January 7, 2026, CERo Therapeutics Holdings, Inc., a Delaware corporation (the “Company”), published a presentation, which it plans to use in meetings with investors, analysts and others. A copy of this presentation is furnished hereto as Exhibit 99.1.

The information in this Item 7.01 and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 8.01 Other Events.

On January 7, 2026, the Company issued a press release titled “CERo Therapeutics Provides Clinical Update on Phase 1 Trial of CER-1236 in AML (CertainT-1) Highlighting Key Safety Data and Platelet Transfusion-Free Interval Observed in a Patient with Myelodysplastic Syndrome/AML.” A copy of the press release is attached herewith as Exhibit 99.2 to this Current Report on Form 8-K and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Presentation (January 2026)
99.2		Press release dated January 7, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: January 7, 2026	CERO THERAPEUTICS HOLDINGS, INC.
	By:	/s/ Chris Ehrlich
	Name:	Chris Ehrlich
	Title:	Chief Executive Officer

2

FAQ

What did CERo Therapeutics Holdings, Inc. (CERO) disclose in this 8-K?

The company disclosed that it published an investor presentation and issued a press release providing a clinical update on its Phase 1 trial of CER-1236 in AML (CertainT-1). Both documents are attached as exhibits.

How will CERo Therapeutics (CERO) use the new investor presentation?

The presentation will be used in meetings with investors, analysts and others and is attached as Exhibit 99.1 for reference.

What is the focus of CERo Therapeutics’ clinical press release mentioned in the filing?

The press release, attached as Exhibit 99.2, provides a clinical update on the Phase 1 trial of CER-1236 in AML (CertainT-1), highlighting key safety data and a platelet transfusion-free interval observed in a patient with myelodysplastic syndrome/AML.

Are the CERo Therapeutics presentation and press release considered filed under the Exchange Act?

The information in Item 7.01, including Exhibit 99.1, is expressly stated as furnished and not deemed filed for purposes of Section 18 of the Exchange Act, or incorporated by reference except where specifically referenced.

Where can investors find the new CERo Therapeutics (CERO) materials?

Investors can find the investor presentation as Exhibit 99.1 and the press release as Exhibit 99.2 to this current report.

Who signed the CERo Therapeutics 8-K report?

The report was signed on behalf of CERo Therapeutics Holdings, Inc. by Chris Ehrlich, Chief Executive Officer.